Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Clinical Practice Guidelines – Myelodysplastic Syndromes

 

Myelodysplastic Syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Published in 2020 – Ann Oncol (2020)
Authors: P. Fenaux, D. Haase, V. Santini, G.F. Sanz, U. Platzbecker & U. Mey, on behalf of the ESMO Guidelines Committee

Myelodysplastic syndromes (MDS) are clonal haematopoietic stem cell (HSC) disorders predominating in the elderly, with a median age at diagnosis of ~70 years. This ESMO Clinical Practice Guideline provides key recommendations for managing myelodysplastic syndromes. It covers diagnosis, classification, staging and risk assessment of myelodysplastic syndromes. Treatment recommendations for lower- and higher-risk myelodysplastic syndromes are also provided. All recommendations were compiled by a multidisciplinary group of experts. Recommendations are based on available scientific data and the authors’ expert opinion

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings